         |
List of publications since 1998
For
more detailed information select 'Abstract' or select 'Full Article' to
download a printable version. (PDF format).
| [Date] |
[Publication] |
 |
| 2008 |
AIDS. 22:367-76 |
|
|
|
Bannister WP, Ruiz L, Cozzi-Lepri A, Mocroft A, Kirk O, Staszewski S, Loveday C, Karlsson A, Monforte A, Clotet B, Lundgren JD; EuroSIDA study group.
Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.
|
| 2008 |
Mol Pharmacol. [Epub ahead of print] |
|
|
|
Moncunill G, Armand-Ugon M, Clotet I, Pauls E, Ballana E, Llano A, Romagnoli B, Vrijbloed JW, Gombert FO, Clotet B, De Marco S, Este JA.
Anti-HIV Activity and Resistance Profile of the CXCR4 Antagonist POL3026.
|
| 2008 |
J Acquir Immune Defic Syndr. 47:36-49 |
|
|
|
Opravil M, Sasadeusz J, Cooper DA, Rockstroh JK, Clumeck N, Clotet B, Montaner J, Torriani FJ, Depamphilis J, Dieterich DT.
Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection.
|
| 2008 |
AIDS. 22:203-10 |
|
|
|
Kuntzen T, Tural C, Li B, Feldmann G, Kupfer B, Nischalke HD, Clotet B, Sauerbruch T, Rockstroh JK, Spengler U.
Intrahepatic mRNA expression in hepatitis C virus and HIV/hepatitis C virus co-infection: infiltrating cells, cytokines, and influence of HAART.
|
| 2008 |
AIDS. 22:23-31 |
|
|
|
Moncunill G, Armand-Ugón M, Pauls E, Clotet B, Esté JA.
HIV-1 escape to CCR5 coreceptor antagonism through selection of CXCR4-using variants in vitro.
|
| 2008 |
J Antimicrob Chemother. 61:400-4 |
|
|
|
Negredo E, Puigdomènech I, Marfil S, Puig J, Pérez-Alvarez N, Ruiz L, Rey-Joly C, Clotet B, Blanco J.
Association between HIV replication and cholesterol in peripheral blood mononuclear cells in HIV-infected patients interrupting HAART.
|
| 2008 |
Virology. 372:421-9 |
|
|
|
Senserrich J, Pauls E, Armand-Ugón M, Clotet-Codina I, Moncunill G, Clotet B, Esté JA.
HIV-1 resistance to the anti-HIV activity of a shRNA targeting a dual-coding region.
|
| 2008 |
J Pharmacol Exp Ther. 324:558-67 |
|
|
|
Minuesa G, Purcet S, Erkizia I, Molina-Arcas M, Bofill M, Izquierdo-Useros N, Casado FJ, Clotet B, Pastor-Anglada M, Martinez-Picado J.
Expression and functionality of anti-human immunodeficiency virus and anticancer drug uptake transporters in immune cells.
|
| 2008 |
Virus Res. 131:260-70 |
|
|
|
Franco S, Clotet B, Martínez MA.
A wide range of NS3/4A protease catalytic efficiencies in HCV-infected individuals.
|
| 2008 |
J Antimicrob Chemother. 61:13-6 |
|
|
|
CLotet, B
Once-daily dosing of nevirapine in HAART.
|
| 2008 |
J Antimicrob Chemother. 61:206-9 |
|
|
|
Llibre JM, Domingo P, del Pozo MA, Miralles C, Galindo MJ, Viciana I, Moreno S, Schapiro JM, Clotet B.
Long-distance interactive expert advice in highly treatment-experienced HIV-infected patients.
|
| 2008 |
Immunology. Aug 28. [Epub ahead of print] |
|
|
|
Darwich L, Coma G, Peña R, Bellido R, Blanco EJ, Este JA, Borras FE, Clotet B, Ruiz L, Rosell A, Andreo F, Parkhouse RM, Bofill M.
Secretion of interferon-gamma by human macrophages demonstrated at the single-cell level after costimulation with interleukin (IL)-12 plus IL-18.
|
| 2008 |
AIDS. 2008 Aug 20. [Epub ahead of print] |
|
|
|
Elliott JH, Lynen L, Calmy A, De Luca A, Shafer RW, Zolfo M, Clotet B, Huffam S, Boucher CA, Cooper DA, Schapiro JM.
Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching.
|
| 2008 |
Antimicrob Agents Chemother. 2008 Aug 25. [Epub ahead of print] |
|
|
|
Moltó J, Santos JR, Pérez-Álvarez N, Cedeño S, Miranda C, Khoo S, Else L, Llibre JM, Valle M, Clotet B.
DARUNAVIR INHIBITORY QUOTIENT PREDICTS THE 48-WEEK VIROLOGICAL RESPONSE TO DARUNAVIR-BASED SALVAGE THERAPY IN HIV-INFECTED PROTEASE INHIBITOR-EXPERIENCED PATIENTS.
|
| 2008 |
ChemMedChem. 2008 Jul 31. [Epub ahead of print] |
|
|
|
Pettersson S, Pérez-Nueno VI, Ros-Blanco L, Puig de La Bellacasa R, Rabal MO, Batllori X, Clotet B, Clotet-Codina I, Armand-Ugón M, Esté J, Borrell JI, Teixidó J.
Discovery of Novel Non-Cyclam Polynitrogenated CXCR4 Coreceptor Inhibitors.
|
| 2008 |
J Antimicrob Chemother. 2008 Jul 23. [Epub ahead of print] |
|
|
|
Llibre JM, Santos JR, Puig T, Moltó J, Ruiz L, Paredes R, Clotet B.
Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz.
|
| 2008 |
N Engl J Med. 2008 Jul 24;359(4):355-65. |
|
|
|
Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Teppler H, Nguyen BY; BENCHMRK Study Teams.
Collaborators (120)
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
|
| 2008 |
N Engl J Med. 2008 Jul 24;359(4):339-54. |
|
|
|
Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Nguyen BY, Teppler H; BENCHMRK Study Teams.
Collaborators (120)
Raltegravir with optimized background therapy for resistant HIV-1 infection.
|
| 2008 |
Antiviral Res. 2008 Jul 3. [Epub ahead of print] |
|
|
|
Bosch B, Grigorov B, Senserrich J, Clotet B, Darlix JL, Muriaux D, Este JA.
A clathrin-dynamin-dependent endocytic pathway for the uptake of HIV-1 by direct T cell-T cell transmission.
|
| 2008 |
J Antimicrob Chemother. 2008 Jun 30. [Epub ahead of print] |
|
|
|
Moltó J, Valle M, Miranda C, Cedeño S, Miranda J, Santos JR, Negredo E, Vilaró J, Costa J, Clotet B.
Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach.
|
| 2008 |
AIDS. 2008 Jul 11;22(11):1313-22. |
|
|
|
Autran B, Murphy RL, Costagliola D, Tubiana R, Clotet B, Gatell J, Staszewski S, Wincker N, Assoumou L, El-Habib R, Calvez V, Walker B, Katlama C; ORVACS Study Group.
Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452).
|
| 2008 |
Antivir Ther. 2008;13(3):399-407. |
|
|
|
Deforche K, Cozzi-Lepri A, Theys K, Clotet B, Camacho RJ, Kjaer J, Van Laethem K, Phillips A, Moreau Y, Lundgren JD, Vandamme AM; EuroSIDA Study Group.
Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response.
|
| 2008 |
Clin Infect Dis. 2008 Jul 15;47(2):266-85. |
|
|
|
Hirsch MS, Günthard HF, Schapiro JM, Brun-Vézinet F, Clotet B, Hammer SM, Johnson VA, Kuritzkes DR, Mellors JW, Pillay D, Yeni PG, Jacobsen DM, Richman DD.
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.
|
| 2008 |
HIV Clin Trials. 2008 May-Jun;9(3):177-85. |
|
|
|
Lifson AR; INSIGHT Cause of Death Writing Group, Belloso WH, Carey C, Davey RT, Duprez D, El-Sadr WM, Gatell JM, Gey DC, Hoy JF, Krum EA, Nelson R, Nixon DE, Paton N, Pedersen C, Perez G, Price RW, Prineas RJ, Rhame FS, Sampson J, Worley J.
Collaborators (43)
Determination of the underlying cause of death in three multicenter international HIV clinical trials.
|
| 2008 |
J Acquir Immune Defic Syndr. 2008 Jul 1;48(3):324-33. |
|
|
|
Bannister WP, Cozzi-Lepri A, Clotet B, Mocroft A, Kjaer J, Reiss P, von Wyl V, Lazzarin A, Katlama C, Phillips AN, Ruiz L, Lundgren JD; EuroSIDA study group.
Collaborators (175)
Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study.
|
| 2008 |
Antivir Ther. 2008;13(2):231-40. |
|
|
|
Negredo E, Garrabou G, Puig J, Lòpez S, Morén C, Bellido R, Ayen R, Cardellach F, Miró O, Clotet B.
Partial immunological and mitochondrial recovery after reducing didanosine doses in patients on didanosine and tenofovir-based regimens.
|
| 2008 |
HIV Med. 2008 May 13. [Epub ahead of print] |
|
|
|
Llibre J, Bonjoch A, Iribarren J, Galindo M, Negredo E, Domingo P, Pérez-Alvarez N, Martinez-Picado J, Schapiro J, Clotet B; the HIV Conference Call study group.
Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study.
|
| 2008 |
Top HIV Med. 2008 Mar-Apr;16(1):62-8. |
|
|
|
Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD.
Update of the Drug Resistance Mutations in HIV-1: Spring 2008.
|
| 2008 |
Retrovirology. 2008 Mar 31;5:32. |
|
|
|
Puigdomènech I, Massanella M, Izquierdo-Useros N, Ruiz-Hernandez R, Curriu M, Bofill M, Martinez-Picado J, Juan M, Clotet B, Blanco J.
HIV transfer between CD4 T cells does not require LFA-1 binding to ICAM-1 and is governed by the interaction of HIV envelope glycoprotein with CD4.
|
| 2008 |
HIV Med. 2008 Apr;9(4):221-6. |
|
|
|
De Lazzari E, León A, Arnaiz JA, Martinez E, Knobel H, Negredo E, Clotet B, Montaner J, Storfer S, Asenjo MA, Mallolas J, Miró JM, Gatell JM.
Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts.
|
| 2008 |
AIDS. 2008 Mar 30;22(6):737-40. |
|
|
|
Angus B, Lampe F, Tambussi G, Duvivier C, Katlama C, Youle M, Williams I, Clotet B, Fisher M, Post FA, Babiker A, Phillips A; TILT Trial Steering Committee.
TILT: a randomized controlled trial of interruption of antiretroviral therapy with or without interleukin-2 in HIV-1 infected individuals.
|
|
